Ditch Labs Inc. Enters Agreement with Meditrial Europe Ltd to Conduct First Clinical Trial

Ditch Labs Inc. ("Ditch Labs") is pleased to announce that it has entered into an agreement with Meditrial Europe Ltd ("Meditrial") to conduct Ditch Labs' first clinical trial. The trial, which will take place in the Czech Republic, will test the pharmacokinetic, safety, and efficacy of the Ditch system.

The Ditch system consists of a revolutionary device designed to help patients quit smoking, paired to a digital therapeutic application. It has the potential to significantly improve patient outcomes and reduce the negative health effects of smoking. The clinical trial will provide valuable data on the performance of the Ditch system and help determine its potential for widespread use.

"We are very excited to partner with Meditrial for our first clinical trial," said Laurent Laferriere, CEO of Ditch Labs. "This marks an important milestone in our journey, after years of research, product development and preclinical testing. Meditrial is a leading clinical research organization with a strong track record in conducting high-quality clinical trials. We believe this partnership will be instrumental in the successful completion of our trial and the advancement of the Ditch system."

"As Chief Scientific Officer of Ditch Labs, I am particularly enthusiastic about this clinical trial," said Dr. Christelle Luce. “An evidence-based approach is essential to understand the impact of the various components of our treatment on successful smoking cessation, reduction of nicotine withdrawal symptoms, and improvement of quality of life. This randomized controlled trial will provide us with valuable data that will inform future development and the regulatory approval process of the Ditch treatment.”

"We are thrilled to be working with Ditch Labs on this exciting clinical trial," said Dr. Monica Tocchi, Founder and CMO of Meditrial. "The Ditch system has the potential to make a real difference in the lives of patients, and we are committed to helping Ditch Labs bring this innovative product to market."

The clinical trial is expected to begin in the coming months and will enroll a diverse group of adult cigarette smokers. The results of the trial will be used to inform Ditch Labs about its medical device, but also about the pharmacological and psychological aspects of its treatment.

For more information about Ditch Labs and the Ditch system, please click here.

About Ditch Labs Inc.

Ditch Labs is a medical device company dedicated to improving patient outcomes through innovative technologies. The company's flagship product, the DitchPen™, is a revolutionary device designed to help patients quit smoking and reduce the negative health effects of smoking.

About Meditrial Europe Ltd

Meditrial is a leading clinical research organization with a strong track record in conducting high-quality clinical trials. The company has a global network of experienced professionals and state-of-the-art facilities, making it a preferred partner for pharmaceutical and medical device companies seeking to conduct clinical research.

Ditch Labs Wins The Jury’s First Prize Following Acfas Competition’s 6th Edition

MONTREAL, QC/March, 2022 – The 6th edition of Acfas competition occurred on March 29th and was broadcasted live.

Following the event, the research team of Ditch Labs, Inc. led by Research Director and Partner Christelle Luce, Co-Founder and CTO Olivier Bourbonnais, Pharmacologist Mehdi El Hassani, Researcher in Psychology Éric Hanigan and Financial Analyst Naïl Sousa Cordeiro as part of the 6 finalist teams, wins the jury’s first prize. The prize includes a value of more than $22,000 in consulting and scholarship services. The company sincerely thanks Acfas and the jury for the opportunity to participate.

“We couldn’t be happier following the performance of our research team which includes Christelle Luce, P.h.D, Olivier Bourbonnais, Mehdi El Hassani, Éric Hanigan and Naïl Sousa Cordeiro during yesterday’s competition of Acfas. It is an honor to have participated and to be the winning team of the jury’s first prize! Congratulations to all the participants and thanks to the jury for their time and support.” - Ditch Labs, Public Statement

Ditch Labs Appoints Moishe Liberman, MD, PhD, FACS, FRCSC, as Chief Medical Officer

MONTREAL, QC/March 23, 2022 – Ditch Labs, Inc. is honored to appoint Dr. Moishe Liberman as Chief Medical Officer (CMO). Dr. Liberman is a minimally invasive thoracic surgeon trained at Harvard University who has run over 40 clinical trials at the CHUM Research Center over the last 13 years in Thoracic Surgical Oncology.

“It is a pleasure to be joining Ditch Labs’ stellar team to participate in developing such an innovative and revolutionary system. Seeing firsthand the consequences of tobacco use and the unmet needs caused by the lack of effective treatments, I am deeply motivated to contribute to the new paradigm that Ditch is creating in smoking cessation.”

- Dr. Moishe Liberman, Chief Medical Officer at Ditch Labs

Some of the responsibilities assumed by Dr. Liberman will be strategic supervision of the company’s medical and clinical affairs, including aiding in recruitment of various partners, establishing the corporation’s scientific advisory board and key opinion leadership and supporting in the design, planning and execution of clinical trials.

“Since the beginning, one of Ditch’s missions is to bring together the brightest minds to solve the leading cause of preventable death. The appointment of Dr. Liberman as CMO marks an important step in building a solid executive team, bringing us closer to reaching our first clinical milestone by the end of the year.”

- Laurent Laferrière, Co-Founder and CEO at Ditch Labs

As Ditch prepares for its First In Human study, the company looks forward to working alongside such a renowned physician with direct access to valuable resources and patients in dire need of effective smoking cessation treatments.

Ditch Labs Announced As Finalist Of ACFAS Competition’s 6th Edition

MONTREAL, QC/March, 2022 – Led by Research Director and Partner Christelle Luce, Co-Founder and CTO Olivier Bourbonnais, Pharmacologist Mehdi El Hassani, Researcher in Psychology Éric Hanigan, Financial Analyst Naïl Sousa Cordeiro and Medical Devices Consultant Jean-Pierre Desmarais, Ditch Labs, Inc. becomes finalist of the renowned Génies en affaires competition which will occur live on Facebook on March 29th, 2022. The event will include a 5-minute question period following an 80-second sales pitch and a vote from the public to choose the winners.

Ditch Receives $350,000 Of Funding From Québec’s Ministère de l’Économie et de l’Innovation (MEI), In Collaboration With MEDTEQ+ And PromptInnov

MONTREAL, QC/February, 2022 – Ditch Labs, Inc. receives $350,000 of additional funding from the MEI. The funding operation is led by MEDTEQ+ and PromptInnov as holders of the HI_DOS program which aims to support the security certification, regulatory approval processes and interoperability activities of Quebec companies wishing to market connected objects in the health sector.

Ditch Partners With The CRIQ, Investissement Québec's World-Renowned Laboratory, For Nonclinical Testing

MONTREAL, QC/January, 2022 – Ditch Labs, Inc.’s partnership with the CRIQ led by Research Director and Partner Christelle Luce, Co-Founder and CTO Olivier Bourbonnais and Pharmacologist Mehdi El Hassani, will serve the objective of characterizing the aerosol generated by the DitchPen™. The company intends to present a toxicology report to the FDA and Health Canada in order to receive a Clinical Trial Authorization (Health Canada) and an Investigational New Drug approval (FDA).

Ditch Completes Successful Integration And Testing Of Its Second-Generation Alpha Product, Ready For Nonclinical Testing

MONTREAL, QC/January, 2022 – Ditch Labs, Inc. completing the successful integration and testing of its second-generation alpha product marks a green status for the upcoming nonclinical testing. The new alpha prototypes led by Co-Founder and CTO Olivier Bourbonnais and Hardware Expert François Bélanger include newer designs optimized for manufacturing along with a more effective mechanism allowing the device to be more accurate.

Ditch Labs Receives Funding From The National Research Council's IRAP Program

MONTREAL, QC/December, 2021 – Following the partnership between Ditch Labs, Inc. and the CRIM along with professional recommendations, the company’s application for the non-dilutive funding of the National Research Council’s IRAP program is now approved. These additional funds will finance the fees of the CRIM researchers.

Ditch Partners Up With The Computer Research Institute of Montréal (CRIM) To Develop Its Treatment Algorithms

MONTREAL, QC/December, 2021 – The partnership of Ditch Labs, Inc. with the CRIM to develop its treatment algorithms led by Research Director and Partner Christelle Luce, Co-Founder and CTO Olivier Bourbonnais, Software Director Étienne Bélanger and Researcher Gabrielle Toupin, will strengthen the cybersecurity of its solutions and allow the company to develop algorithms based on the data it collects from the DitchPen™ and from the DitchApp™, among other important aspects.

Ditch Files First US And International Patent Protecting Their Innovative Precision Dosing Technology

MONTREAL, QC/November, 2021 – Ditch Labs, Inc. with the assistance of law and IP firm Fasken, files its first US patent at the USPTO along with an international patent with PCT services from the WIPO in order to secure ownership and intellectual property rights for the company’s innovative solutions. This filing allows the company to secure technological advancements and paves the way for other patent applications further in the company's development process.